HP5: USE OF THE SOJA METHOD FOR CHOOSING A HMG CO-A REDUCTASE INHIBITOR (STATIN) IN IRELAND  by Heerey, A et al.
406 Abstracts
use of single-use equipment rather than reusable equip-
ment also increases the variable unit costs significantly.
SESSION II
HEALTH POLICY II
HP4
PRICING OF PHARMACEUTICALS IN CANADA 
AND EUROPE: A COMPARATIVE ANALYSIS
Palmer WN
Palmer D’Angelo Consulting Inc, Ottawa, ON, Canada
OBJECTIVES: This paper compares pricing and reim-
bursement of pharmaceuticals between Canada and se-
lected European countries.
METHODS: We examined the pricing and reimburse-
ment schemes and cost-containment initiatives adopted
in Europe and Canada and their impact on prices of ex-
isting and new medications. Published data from the Pat-
ented Medicine Prices Review Board (PMPRB) provides
international price comparisons for patented medicines
available in Canada. Prices for 13 new active substances
first marketed in Canada in 2000 were assembled for
Canada and six European countries. For comparative
purposes, prices in the United States were also included in
the analysis.
RESULTS: Drug prices in Canada are typically lower
than prices in Germany, Sweden, Switzerland, and the
UK but higher than prices in France and Italy. Patented
Drugs were 8% lower than the international median as
measured by the PMPRB. However, for new drugs intro-
duced in 2000, prices were, on average, 8.3% higher than
those in Europe, although most were within the range of
European prices. Prices in Canada and Europe were al-
most always lower than those in the United States.
CONCLUSIONS: The health-care systems in Canada
and Europe are fairly similar, as are the drug pricing and
reimbursement schemes. However, local policies (e.g.,
reference pricing, generic substitution, pharmacoeconom-
ics) can result in significant international price variations
and the potential for parallel importation. Cost-effective-
ness and international price comparisons play an impor-
tant role in most major markets. The prices of pharma-
ceuticals in Canada are comparable to those in Europe
although there is a trend for Canadian prices to be
higher. Although pharmaceutical prices in Canada and
Europe appear to be lower than in the United States,
there are important differences in the health-care systems
as well as in the reimbursement mechanisms that make
price comparisons with the US problematic.
HP5
USE OF THE SOJA METHOD FOR CHOOSING A 
HMG CO-A REDUCTASE INHIBITOR (STATIN)
IN IRELAND
Heerey A, McGowan B, Barry M
National Centre for Pharmacoeconomics, Dublin, Ireland
OBJECTIVE: The System of Objectified Judgement
Analysis (SOJA) method is a recognized, standardized
system, which aims to distinguish a medication of choice
from a class of drugs. It combines expert opinion on pri-
orities during prescription, with clinical evidence per in-
dividual drug. We used the SOJA method in the Irish set-
ting for statins and compared the results to their actual
prescribing patterns in Ireland.
METHODS: A questionnaire was sent to 1,705 Irish gen-
eral practitioners (GPs) asking them to rank between 0
and 10 the relative importance of 11 criteria when pre-
scribing statins. These average results were assigned to
the SOJA method. The higher the overall SOJA score per
medication, the better the statin performed and the more
evidence to support the prescription of this drug over
others in the same class. The SOJA results were com-
pared to the number of statin prescriptions for public pa-
tients at the time the questionnaire was completed (Aug/
Sept 2000).
RESULTS: There was a 42% reply rate. The average or-
der of importance, as rated by the GPs were clinical effi-
cacy (9.26), side effects (8.24), drug interactions (7.93),
dosage frequency (7.53), clinical endpoint studies (7.50),
number of approved indications (7.07), documentation
(6.96), cost-effectiveness (6.95), bioavailablility (6.69),
absorption (6.46) and number of formulations (5.55).
The resulting SOJA score (with number of prescriptions)
were simvastatin 64.6 (7,150), atorvastatin 59.5 (19,770),
pravastatin 59.4 (34,736), cerivastatin 56.3 (3,500) and
fluvastatin 51.4 (4,134).
CONCLUSION: This study indicated that simvastatin
should be the statin of choice in Ireland followed by ator-
vastatin or pravastatin. However, pravastatin is by far
the most widely prescribed statin. This suggests that non-
rationale factors such as marketing may be influencing
prescribing in Ireland. Additionally, despite the fact that
statins represent one of the most expensive long-term
therapies, Irish GPs rank cost-effectiveness low on the list
of priorities during their prescription.
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OBJECTIVE: Our study had two objectives. The first
was to disaggregate historical drug expenditure increases
into three components: price increase, utilization in-
crease, and product shift. The second objective was to
demonstrate the potential impact of pipeline drugs on an-
nual drug-expenditure increases, factoring in what has
been observed historically for newer drugs.
METHODS: The method for calculating pure price infla-
tion involved a fixed set of drugs and measured the utili-
zation-weighted mean of annual percentage increases.
